Decitabine in myelodysplastic syndromes: A viewpoint

Drugs

Volumn 66, Issue 7, 2006, Pages 959-

  Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTOSONE PHOSPHOGUANINE; DNA METHYLTRANSFERASE; GUANINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; DNA METHYLATION; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; MYELODYSPLASTIC SYNDROME; NOTE; PROMOTER REGION; QUALITY OF LIFE;

ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; AZACITIDINE; CLINICAL TRIALS; HUMANS; MOLECULAR STRUCTURE; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 33744906758     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666070-00012     Document Type: Note

References (5)

1. Silverman LR, Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40
2. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000 Mar; 18: 956-62
3. Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106 (8): 1794-803
4. Issa J-PJ, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 Mar 1; 103 (5): 1635-40
5. 2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract no. 2522]. Blood 2005 Nov; 106 (11): 708